Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Melatonin can improve sleep quality and reduce insomnia in patients with sleep apnea, but it does not treat the underlying breathing pauses that define the condition itself. While clinical research shows meaningful improvements in sleep quality scores and daytime sleepiness, emerging 2025 research has raised new concerns about cardiovascular risks with long-term use.
If you or a loved one has sleep apnea and is considering melatonin—or already taking it—understanding what the evidence actually shows is essential before deciding whether it’s right for you. Sleep apnea affects millions of people, particularly older adults, and disrupts nighttime rest in ways that melatonin alone cannot fix. Many people naturally turn to melatonin as a simple, over-the-counter option when they struggle to sleep, but the relationship between melatonin and sleep apnea is more nuanced than simply taking a supplement at bedtime.
Table of Contents
- How Does Melatonin Work in Sleep Apnea Patients?
- What Research Shows About Melatonin’s Effect on Sleep Quality
- Why Melatonin Doesn’t Address the Core Problem
- Melatonin Dosage and Common Side Effects
- Drug Interactions and the Emerging Cardiovascular Concern
- When Melatonin Might Actually Be Helpful
- Moving Forward: Sleep Apnea Treatment and Emerging Research
- Conclusion
How Does Melatonin Work in Sleep Apnea Patients?
melatonin is a hormone naturally produced by the pineal gland in the brain that signals your body when it’s time to sleep. In healthy sleepers, melatonin levels rise in the evening and fall in the morning, helping regulate the sleep-wake cycle. However, approximately 25% of people with obstructive sleep apnea have altered nighttime melatonin secretion, with significantly decreased peak melatonin levels. This disruption may contribute to the sleep fragmentation and poor sleep quality that characterize sleep apnea.
When melatonin supplementation is given to sleep apnea patients, it appears to help restore some of the sleep architecture that breathing pauses have disrupted. The hormone doesn’t stop the apneas themselves—the breathing events continue to occur—but it may help patients fall asleep more easily and stay asleep longer despite those interruptions. Think of it this way: if sleep apnea is like a road full of potholes, melatonin doesn’t fill the potholes, but it may help your car stay on the road despite them. This distinction matters because it means melatonin addresses a symptom of sleep apnea (poor sleep quality) rather than the root problem (blocked airways). Understanding this difference helps explain why sleep medicine specialists often hesitate to recommend melatonin as a primary treatment for sleep apnea.
What Research Shows About Melatonin’s Effect on Sleep Quality
A recent randomized double-blinded placebo-controlled trial known as the COMISA trial examined melatonin’s effects on 30 sleep apnea patients. The results were striking: participants taking melatonin showed a Pittsburgh Sleep Quality Index (PSQI) score of 3.84, compared to 10.52 in the placebo group—a statistically significant improvement at P<0.001. The same trial found that melatonin reduced insomnia severity, with Insomnia Severity Index scores of 8.48 versus 14.47 in the placebo group. Additionally, daytime sleepiness improved significantly, with Epworth Sleepiness Scale scores of 6.85 in the melatonin group versus 13.30 in the placebo group. These numbers translate to real improvements in how patients feel.
A person in the study might go from waking multiple times per night despite fatigue to sleeping more continuously, and from struggling through the day with exhaustion to feeling more alert during waking hours. For someone with sleep apnea who is already using a CPAP machine or other treatment, adding melatonin might provide additional relief from the sleep disturbances that persist despite therapy. However, a critical limitation emerged in 2025 that changes how we should interpret these benefits. Preliminary research presented at the American Heart Association’s Scientific Sessions in 2025 analyzed data from over 130,000 adults with insomnia and found that those taking melatonin for one year or longer showed increased risk of heart failure, hospitalization for heart failure, or death from any cause. This finding raises serious questions about whether the short-term sleep improvements documented in the COMISA trial are worth the potential long-term cardiovascular risks. The cardiovascular concern is particularly relevant for dementia care, since heart health and brain health are intimately connected through blood vessel function and oxygen delivery.
Why Melatonin Doesn’t Address the Core Problem
Sleep apnea occurs when the muscles in the throat relax during sleep and partially or completely block the airway. This physical obstruction causes breathing pauses that can last from a few seconds to over a minute, and each pause lowers oxygen levels in the blood. The brain detects these oxygen dips and arousals, which fragments sleep and prevents the restorative deep sleep stages where memory consolidation and brain health recovery happen. Melatonin has no effect on the muscles that collapse, the airway that narrows, or the breathing events themselves. A sleep medicine medical director specializing in sleep disorders noted that she typically does not recommend melatonin to sleep apnea patients precisely because it doesn’t address what’s actually broken.
She noted that melatonin is helpful for specific conditions like jet lag, shift work sleep disorders, or circadian rhythm disturbances—situations where the problem is timing rather than an anatomical blockage. In contrast, sleep apnea is fundamentally an airway problem, not a melatonin deficiency problem. This is an important limitation to understand. If you’re taking melatonin while your sleep apnea remains untreated, you may sleep more deeply due to the melatonin’s effects, but the breathing pauses continue to interrupt that sleep and deprive your brain of oxygen. You might feel slightly less groggy, but your brain is still experiencing repeated oxygen desaturation events that carry long-term health risks.
Melatonin Dosage and Common Side Effects
Melatonin is available over-the-counter, typically in 10mg tablets or lower doses. It’s classified as a dietary supplement rather than a prescription medication, partly because it’s considered to have a high safety profile—it’s non-toxic even at extremely high doses. However, doses exceeding 10mg can cause grogginess, drowsiness, dizziness, or headaches that persist into the next day. Many people assume that if 10mg is good, 20mg or 30mg must be better, but this logic doesn’t apply to melatonin.
Higher doses don’t provide stronger sleep induction beyond a certain point; instead, they increase the likelihood of morning grogginess that can impair cognition and increase fall risk—particularly concerning in dementia care where balance and mental clarity are already compromised. Someone with dementia taking high-dose melatonin might experience increased confusion or dizziness the following day, making caregiving more challenging and increasing safety risks. The practical recommendation for melatonin dosing, when it’s considered appropriate at all, is typically 3-5mg taken 30 minutes before bedtime. Starting lower and increasing only if needed allows you to find the minimum effective dose while minimizing side effects. Many over-the-counter sleep supplements, however, contain 10mg or higher, so careful label reading is essential.
Drug Interactions and the Emerging Cardiovascular Concern
Melatonin can interact with several common medications that older adults and dementia patients often take. These interactions include blood pressure medications, beta-blockers, calcium channel blockers, seizure medications, and blood thinners like Coumadin (warfarin). If you’re taking any of these medications, adding melatonin without consulting your doctor could amplify medication effects or reduce their effectiveness. The 2025 cardiovascular safety concern adds another layer of caution. The study of 130,000+ adults found that melatonin use for one year or longer was associated with increased risk of heart failure and cardiovascular mortality.
While this was a preliminary study presented at a scientific conference (not yet published in a peer-reviewed journal, so interpret with appropriate caution), it represents a significant shift in how we should view melatonin’s long-term safety. For someone with existing heart disease, hypertension, or dementia (which itself involves vascular changes in the brain), this finding should prompt a serious conversation with their physician before starting melatonin. The emerging cardiovascular data is particularly important because it wasn’t anticipated in earlier research. Many people have been taking melatonin for years assuming it’s harmless, but this 2025 analysis suggests that assumption may need revision. This illustrates why medical consultation is not optional before using melatonin for sleep apnea—it’s essential.
When Melatonin Might Actually Be Helpful
While melatonin is not appropriate as primary treatment for sleep apnea, there are specific scenarios where it may offer genuine benefit. If someone has sleep apnea and is already using continuous positive airway pressure (CPAP) therapy effectively, but still experiences insomnia due to circadian rhythm problems, melatonin might help.
For example, an older adult who recently experienced a change in sleep schedule or who has natural age-related circadian rhythm shifts might benefit from melatonin to help reset their sleep timing, used alongside their CPAP treatment. Melatonin is also more appropriate for sleep apnea patients who have clear circadian rhythm disturbances—such as someone who worked night shifts for decades and never fully adjusted back to daytime waking—compared to someone whose sole problem is apneic episodes. In these targeted situations, the short-term use of melatonin (weeks to months rather than years) under medical supervision might provide benefit without the long-term cardiovascular concerns documented in the 2025 research.
Moving Forward: Sleep Apnea Treatment and Emerging Research
The relationship between melatonin and sleep apnea continues to evolve as new research emerges. The positive results from the COMISA trial showed genuine promise, but the 2025 cardiovascular findings remind us that supplement safety requires ongoing monitoring, particularly for long-term use. Future research may clarify which sleep apnea patients are most likely to benefit from melatonin and which populations face unacceptable cardiovascular risks.
In the meantime, the standard approach to sleep apnea—CPAP therapy, positional treatment, weight management, and addressing underlying anatomical factors—remains the evidence-based foundation of care. Melatonin may have a supporting role in specific situations, but only under physician guidance and with careful attention to dosage, drug interactions, and duration of use. As our understanding of melatonin’s long-term effects deepens, personalized medical decision-making becomes increasingly important.
Conclusion
Melatonin may improve sleep quality and reduce insomnia in sleep apnea patients, as shown by the COMISA trial’s significant improvements in sleep quality scores and daytime sleepiness. However, melatonin does not address the breathing pauses that define sleep apnea, and emerging 2025 research raises concerns about cardiovascular risks with use exceeding one year. The supplement works best as a potential adjunct to primary sleep apnea treatment—CPAP or other therapies—rather than as a standalone solution.
If you’re considering melatonin for sleep apnea or dementia-related sleep problems, the essential first step is a conversation with your physician. They can assess your specific situation, review your current medications for potential interactions, help determine whether melatonin is appropriate, and suggest proper dosing if it is. Sleep apnea is a serious condition with real consequences for brain health and longevity, and it deserves treatment strategies grounded in medical evidence rather than supplement assumptions.
